Unfolding of the SARS-CoV-2 Spike Protein Through Infrared and Ultraviolet-C Radiation Based Disinfection
Overview
Affiliations
The spreading of coronavirus from contacting surfaces and aerosols created a pandemic around the world. To prevent the transmission of SARS-CoV-2 virus and other contagious microbes, disinfection of contacting surfaces is necessary. In this study, a disinfection box equipped with infrared (IR) radiation heating and ultraviolet-C (UV-C) radiation is designed and tested for its disinfection ability against pathogenic bacteria and SARS-CoV-2 spike protein. The killing of a Gram-positive, namely, S. aureus and a Gram-negative namely, S. typhi bacteria was studied followed by the inactivation of the spike protein. The experimental parameters were optimized using a statistical tool. For the broad-spectrum antibacterial activity, the optimum condition was holding at 65.61 °C for 13.54 min. The killing of the bacterial pathogen occurred via rupturing the cell walls as depicted by electron microscopy. Further, the unfolding of SARS-CoV-2 spike protein and RNase A was studied under IR and UV-C irradiations at the aforesaid optimized condition. The unfolding of both the proteins was confirmed by changes in the secondary structure, particularly an increase in β-sheets and a decrease in α-helixes. Remarkably, the higher penetration depth of IR waves up to subcutaneous tissue resulted in lower optimum disinfection temperature, <70 °C in vogue. Thus, the combined UV-C and IR radiation is effective in killing the pathogenic bacteria and denaturing the glycoproteins.
Infrared Spectroscopy of SARS-CoV-2 Viral Protein: from Receptor Binding Domain to Spike Protein.
Mancini T, Macis S, Mosetti R, Luchetti N, Minicozzi V, Notargiacomo A Adv Sci (Weinh). 2024; 11(39):e2400823.
PMID: 39001588 PMC: 11497030. DOI: 10.1002/advs.202400823.
Experimental procedures to investigate fibrillation of proteins.
Panda C, Sharma L, Pandey L MethodsX. 2023; 11:102445.
PMID: 37928109 PMC: 10622682. DOI: 10.1016/j.mex.2023.102445.
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases.
Kalita T, Abbasi Dezfouli S, Pandey L, Uludag H Pharmaceutics. 2022; 14(11).
PMID: 36432711 PMC: 9694336. DOI: 10.3390/pharmaceutics14112520.